Tokyo, Japan, July 8: Toray Industries, Inc. today announced the discovery of a novel lead compound that exhibits ferroptosis-inhibiting activity, marking an important step in its efforts to develop innovative therapies for ferroptosis-related diseases. Preclinical studies in animal models of kidney disease have demonstrated promising pharmacological activity, supporting further research and development.
Building on these findings, Toray has initiated a collaborative research program with Professor Kenichi Yamada and his research group at the Faculty of Pharmaceutical Sciences, Kyushu University. The collaboration aims to identify novel biomarkers capable of evaluating the biological effects of ferroptosis inhibition in renal disease models.
Ferroptosis is a regulated form of cell death driven by iron-dependent lipid peroxidation and has emerged as a key mechanism underlying kidney injury and a range of other diseases. However, the dynamic and complex molecular changes associated with ferroptosis have made it difficult to accurately assess disease progression and therapeutic response. Developing reliable biomarkers remains a critical challenge in advancing ferroptosis-targeted drug discovery.
The newly identified lead compound was discovered through Toray’s proprietary drug discovery platform and has demonstrated pharmacological activity in animal models of ischemia-reperfusion acute kidney injury, where ferroptosis is believed to play a significant pathogenic role.
Professor Yamada’s laboratory is internationally recognized for its research on lipid peroxidation and oxidized lipids. The group has developed advanced analytical technologies to detect and characterize oxidized lipid molecules while investigating their roles in disease mechanisms and biomarker discovery.
Under the collaboration, Toray’s lead compound will be evaluated in animal models of ischemia-reperfusion acute kidney injury to investigate molecular changes associated with lipid peroxidation. By integrating Toray’s drug discovery expertise with Kyushu University’s analytical capabilities, the partners aim to identify novel biomarkers that can accurately assess ferroptosis inhibition and support future therapeutic development.
As part of its early partnership strategy, Toray also plans to pursue collaborative research and out-licensing opportunities with biotechnology companies and pharmaceutical partners capable of advancing the program into clinical development.
Through these efforts, Toray seeks to accelerate the development of new therapeutic candidates targeting ferroptosis-related diseases and contribute to addressing significant unmet medical needs in renal disorders and other conditions associated with ferroptotic cell death.